HCW Biologics Finalizes 1-for-6 Reverse Stock Split to Maintain Nasdaq Listing
HCWB has more than doubled off its 52-week low of $0.25.
Summary
HCW Biologics announced the Board's approval and effective date for a 1-for-6 reverse stock split, a critical step to comply with Nasdaq's minimum bid price rule and avoid delisting.
Key Events · Corporate Governance and Compliance · HCWB
-
Reverse Stock Split Approved
The Board of Directors approved a 1-for-6 reverse stock split on June 24, 2026, following shareholder authorization on June 15, 2026.
-
Effective Date Set
The reverse stock split will become effective at 12:01 a.m. Eastern Time on June 30, 2026, with trading on a split-adjusted basis under the existing symbol 'HCWB'.
-
Nasdaq Compliance
The split is intended to ensure ongoing compliance with Nasdaq's Bid Price Rule and additional requirements from the Nasdaq Hearings Panel, preventing automatic delisting.
-
Share Count Adjustment
Outstanding shares will decrease from 9,581,079 to approximately 1,596,849 post-split. The total authorized shares remain unchanged at 250,000,000.
Analysis · HCWB · Life Sciences
This 8-K confirms the execution of a previously authorized reverse stock split, a critical measure for HCW Biologics to maintain its Nasdaq listing. The company has been under a delisting threat due to its low share price and received a going concern warning. While the split itself does not change the company's fundamental value, it is a necessary step to avoid automatic delisting, which would severely impact liquidity and investor confidence. The large number of authorized shares relative to the post-split outstanding shares still leaves significant room for future dilution.
At the time of this filing, HCWB was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.25 to $7.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.